Hu Pepsinogen I ELISA

KAPEPKT810

DIAsource ImmunoAssays S.A. - Rue du Bosquet, 2 - B-1348 Louvain-la-Neuve - Belgium

Human Pepsinogen I ELISA Kit

Enzyme Linked ImmunoSorbent Assay (ELISA) for the measurement of Human Pepsinogen I Levels in Serum

KAPEPKT810

IN VITRO DIAGNOSTIC

DIAsource ImmunoAssays SA - Rue du Bosquet 2, B-1348 Louvain-la-Neuve, Belgium - Tel: +32 10 84 99 11 - Fax : +32 10 84 99 91

INTENDED USE
This ELISA (enzyme-linked immunosorbent assay) kit is intended for the quantitative determination of human pepsinogen I levels in serum. Determination of human serum pepsinogen I level would be a useful tool in the aid of diagnosing the functional states of acid secreting gastric mucosa.

SUMMARY OF PHYSIOLOGY
Pepsinogen consists of a single polypeptide chain of 375 amino acids with an average molecular weight of 42 kDa. Pepsinogen I is synthesized at gastric chief cells and mucous neck cells, while pepsinogen II is produced not only by gastric chief cells and mucous neck cells, but also by clear mucous cells of antrum, etc. The clinical applications of measuring pepsinogen I and pepsinogen II are a useful aid in diagnosing severe atrophic gastritis and stomach cancer. It was suggested that the measurement of serum pepsinogens served as a “serological biopsy” for predicting the presence of atrophic gastritis or superficial gastritis.

Atrophic Gastritis: It was found that a serum pepsinogen I levels falling to less than 20 ng/ml was highly specific for severe atrophic gastritis. It is also observed that serum pepsinogen I levels fell with increasing severity of mucosal damage in atrophic gastritis. The diagnostic sensitivity and specificity of serum pepsinogen I level for advanced atrophic corpus gastritis are about 92% and 90% respectively. On the other hand, the decrease in serum pepsinogen I levels in patients with pernicious anemia and atrophic gastritis was found to be associated with normal or raised pepsinogen II levels. Therefore, a pepsinogen I/pepsinogen II ratio is significantly lower than those with superficial gastritis or normal remnant mucosa.

Stomach Cancer: Low serum pepsinogen I levels were found in patients with gastric cancer, with a threefold higher incidence. Other studies have concluded that low serum pepsinogen I levels may identify persons at increased risk for intestinal types of stomach cancer.

Duodenal Ulcer: A low serum pepsinogen I level can exclude a diagnosis of duodenal ulcer. Although a high pepsinogen I level has less clinical use for establishing the diagnosis of a duodenal ulcer, the combination of hypergastrinemia and a highly elevated serum pepsinogen I strongly suggests the possibility of the Zollinger-Ellison syndrome.

ASSAY PRINCIPLE
This ELISA is designed, developed and produced for the quantitative measurement of human pepsinogen I level in serum sample. The assay utilizes the two-site “sandwich” technique with two selected monoclonal antibodies that bind to different epitopes of human pepsinogen I without any cross-reaction to human pepsinogen II.

Assay calibrators, controls and patient serum samples containing human pepsinogen I are added directly to microtiter wells of microplate that was coated with streptavidin. Simultaneously, a biotinylated antibody and a horseradish peroxidase conjugated antibody are added to each well. After the first incubation period, the wall of microtiter well captures the biotinylated antibody as well as an immuno complex in the form of “streptavidin – biotin-antibody – pepsinogen I – HRP-antibody”. Unbound proteins as well as unbound HRP conjugated antibody in each microtiter well are removed in the subsequent washing step. The well is incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the detecting antibody bound to the pepsinogen I on the wall of the microtiter well is directly proportional to the amount of pepsinogen I in the sample. A calibrator curve is generated by plotting the absorbance versus the respective human pepsinogen I concentration for each calibrator on Point-to-Point, CubicSpline or 4-Parameter plot. The concentration of human pepsinogen I in test samples is determined directly from this calibrator curve.

REAGENTS: Preparation and Storage
This test kit must be stored at 2 – 8°C upon receipt. For the expiration date of the kit refer to the label on the kit box. All components are stable until this expiration date.

Prior to use allow all reagents to come to room temperature. Reagents from different kit lot numbers should not be combined or interchanged.

1. [ꟷ] **Streptavidin Coated Microplate**

   One microplate with 12 x eight strips (96 wells total) coated with streptavidin. The plate is framed and sealed in a foil Ziploc bag with a desiccant. This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

2. | Ab | HRP | CONC | **Detecting Antibody**

   One vial contains 0.6 mL concentrated horseradish peroxidase (HRP) conjugated anti-human pepsinogen I detecting antibody in a stabilized protein matrix. This reagent must be diluted with dilution buffer before use. This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

3. | Ab | BIOT | CONC | **Capture Antibody**

   One vial contains 0.6 mL concentrated biotinylated anti-human pepsinogen I capture antibody in a stabilized protein matrix. This reagent must be diluted with dilution buffer before use. This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

4. | DIL | BUF | **Dilution buffer**

   One vial contains 12 mL ready to use buffer. It should be only used for detecting and capture antibody dilution according to the assay procedures. This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

5. | WASH | SOLN | CONC | **Washing buffer**

   One bottle contains 30 mL of a 30 fold concentrate. Before use the contents must be diluted with 870 mL of distilled water and mixed well. Upon dilution this yields a working wash solution containing a surfactant in phosphate buffered saline with a non-azide preservative. The diluted solution should be stored at room temperature and is stable until the expiration date on the kit box.

6. | CHROM | TMB | **TMB-Substrate solution**

   One bottle contains 12 mL of tetramethylbenzidine (TMB) with hydrogen peroxide. This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

7. | STOP | SOLN | **Stop Solution**

   One bottle contains 12 mL of 0.5 M sulfuric acid. This reagent should be stored at 2 – 8°C or room temperature and is stable until the expiration date on the kit box.

8. | CAL | N | **Calibrators 0 - 5**

   Six vials each contain lyophilized human pepsinogen I in a bovine serum albumin based matrix with a non-azide preservative. **Refer to vials for exact concentration for each calibrator.** All the calibrators should be reconstituted with DI-water and stored at -20°C or below after the first use with up to 3 freeze cycles.

9. | CONTROL | N | **Controls 1 - 2**

   Two vials each contains lyophilized human pepsinogen I in a bovine serum albumin based matrix with a non-azide preservative. **Refer to vials for exact concentration range for each control.** Both controls should be reconstituted with distilled water and stored at -20°C or below after the first use with up to 3 freeze cycles.

SAFETY PRECAUTIONS

The reagents contained in this kit must be used in a professional environment and is intended for in-vitro diagnostic use. The source material for reagents containing bovine serum was derived in the contiguous 48 United States. It was obtained only from healthy donor animals maintained under veterinary supervision and found free of contagious diseases. Wear gloves while performing this assay and handle these reagents as if they are potentially infectious. Avoid contact with reagents containing TMB, hydrogen peroxide, or sulfuric acid. TMB may cause irritation to skin and mucous membranes and cause an allergic skin reaction. TMB is a suspected carcinogen. Sulfuric acid may cause severe irritation on contact with skin. Do not get in eyes, on skin, or on clothing. Do not ingest or inhale fumes. On contact, flush with copious amounts of water for at least 15 minutes. Use Good Laboratory Practices.

MATERIALS REQUIRED BUT NOT PROVIDED

1. Precision single channel pipettes capable of delivering 20 µL, 25 µL, 100 µL, and 1000 µL, etc.
2. Repeating dispenser suitable for delivering 100 µL.
3. Disposable pipette tips suitable for above volume dispensing.
4. Disposable 12 x 75 mm or 13 x 100 glass tubes.
5. Disposable plastic 1000 mL bottle with caps.
6. Aluminum foil.
7. Deionized or distilled water.
8. Plastic microtiter well cover or polyethylene film.
9. ELISA multichannel wash bottle or automatic (semi-automatic) washing system.
10. Spectrophotometric microplate reader capable of reading absorbance at 450 nm.

SPECIMEN COLLECTION

Only 50 µL of human serum is required for human pepsinogen I measurement in duplicate. No special preparation of individual is necessary prior to specimen collection. However, a 10 hour fasting serum sample is recommended for the test. Whole blood should be collected and must be allowed to clot for minimum 30 minutes at room temperature before the serum is separated by centrifugation (850 – 1500xg for 10 minutes). The serum should be separated from the clot within three hours of blood collection and transferred to a clean test tube. Serum samples should be stored at –20°C or below until measurement. Avoid more than three freeze-thaw cycles of specimen.

ASSAY PROCEDURE

1. Reagent Preparation

(1) Prior to use allow all reagents to come to room temperature. Reagents from different kit lot numbers should not be combined or interchanged.

(2) Washing buffer must be diluted to working wash solution prior to use. Please see REAGENTS section for details.

(3) Reconstitute all assay calibrators and controls by adding **0.5 mL** of demineralized water to the vial of calibrator level 0 and **0.5 mL** demineralized water to the vials of calibrator level 1 - 5 and control 1 & 2. Allow the calibrators and controls to sit undisturbed for 10 minutes, and then mix well by gentle vortexing. Make sure that all solid is dissolved completely prior to use. These reconstituted calibrators and controls must be stored at - 10°C or below. Do not exceed 3 freeze-thaw cycles.

(4) Place a sufficient number of streptavidin coated microwell strips in a holder to run calibrators, controls and unknown samples in duplicate.

(5) Test Configuration

ROW	STRIP 1	STRIP 2	STRIP 3
A	CAL 0	CAL 4	SAMPLE 1
B	CAL 0	CAL 4	SAMPLE 1
C	CAL 1	CAL 5	SAMPLE 2
D	CAL 1	CAL 5	SAMPLE 2
E	CAL 2	C 1	SAMPLE 3
F	CAL 2	C 1	SAMPLE 3
G	CAL 3	C 2	
H	CAL 3	C 2	

(6) Prepare working Detecting Antibody and Capture Antibody mixture by 1:21 fold dilution of the Pepsinogen I Detecting Antibody and the Pepsinogen I Capture Antibody with the dilution buffer. For each strip, is required to mix 1 mL of dilution buffer with the addition of 50 µL of Detecting Antibody and 50 µL Capture Antibody) in a clean test tube or vial. Following is a table that outlines the relationship of strips used and antibody mix prepared

Strip no.	Dilution buffer	Detecting Antibody	Capture Antibody
1	1 mL	50 µL	50 µL
2	2 mL	100 µL	100 µL
3	3 mL	150 µL	150 µL
4	4 mL	200 µL	200 µL
5	5 mL	250 µL	250 µL
6	6 mL	300 µL	300 µL
7	7 mL	350 µL	350 µL
8	8 mL	400 µL	400 µL
9	9 mL	450 µL	450 µL
10	10 mL	500 µL	500 µL
11	11 mL	550 µL	550 µL
12	12 mL	600 µL	600 µL

Note: *this antibody mix should be freshly prepared right before running the assay.*

2. Manual Assay procedure

(1) Add 25 µL of calibrators, controls and patient serum samples into the designated microwell.

(2) Add 100 µL of above antibody mixture to each well

(3) Mix gently and cover the plate with one plate sealer and also with aluminum foil to avoid exposure to light.

(4) Incubate plate at room temperature for 1 hour.

(5) Remove the aluminum foil and plate sealer. Aspirate the contents of each well. Wash each well 5 times by dispensing 350 µL of working wash solution into each well and then completely aspirating the contents. Alternatively, an automated microplate washer can be used.

(6) Add 100 µL of TMB-Substrate solution into each of the wells

(7) Cover the plate with one new plate sealer and also with aluminum foil to avoid exposure to light.

(8) Incubate plate at room temperature for 20 minutes (This inubation period may be reduced to 8-15 min if a lower OD reading is demanded to fit to the plate readers specification).

(9) Remove the aluminum foil and plate sealer. Add 100 µL of Stop Solution into each of the well. Mix gently.

(7) Read the absorbance at 450 nm within 10 minutes in a microplate reader

PROCEDURAL NOTES

1. It is recommended that all calibrators, controls and unknown samples be assayed in duplicate. The average absorbance reading of each duplicate should be used for data reduction and the calculation of results.
2. Keep light sensitive reagents in the original bottles and avoid unnecessary exposure to the light.
3. Store any unused antibody coated strips in the foil Ziploc bag with desiccant to protect from moisture.
4. Careful technique and use of properly calibrated pipetting devices are necessary to ensure reproducibility of the test.
5. Incubation times or temperatures other than those stated in this insert may affect the results.
6. Avoid air bubbles in the microwell as this could result in lower binding efficiency and higher CV% of duplicate reading
7. All reagents should be mixed gently and thoroughly prior to use. Avoid foaming.

INTERPRETATION OF RESULTS

1. Calculate the average absorbance for each pair of duplicate test results.
2. Subtract the average absorbance of the CAL 0 (0 ng/mL) from the average absorbance of all other readings to obtain corrected absorbance.
3. The calibration curve is generated by the corrected absorbance of all calibrators on the ordinate against the calibrator concentration on the abscissa using point-to-point or log-log paper. Appropriate computer assisted data reduction programs may also be used for the calculation of results.
4. It is recommended to use following curve fits: (1) Point-to-Point, or (2) 4-Parameter or (3) CubicSpline.

The human pepsinogen I concentrations for the controls and patient samples are read directly from the calibration curve using their respective corrected absorbance.

EXAMPLE DATA AND CALIBRATION CURVE

A typical absorbance data and the resulting calibration curve from human pepsinogen I ELISA are represented. **This curve should** not be used in lieu of calibration curve run with each assay.

Well I.D.	OD 450 nm Absorbance			Results ng/mL
	Readings	Average	Corrected	
0 ng/mL	0.053 0.050	0.052	0.000	
3 ng/mL	0.119 0.118	0.119	0.067	
10 ng/mL	0.262 0.246	0.254	0.202	
30 ng/mL	0.616 0.622	0.619	0.567	
90 ng/mL	1.565 1.387	1.476	1.424	
300 ng/mL	2.766 2.604	2.685	2.633	
Control 1	0.373 0.363	0.368	0.316	16.2 ng/mL
Control 2	1.692 1.587	1.640	1.588	118 ng/mL



EXPECTED VALUES

Seventy-three normal adult sera were measured with this human pepsinogen I ELISA. The expected normal range is listed in the following table with different percentile cut-off and the median level of this group of population is 62.8 ng/mL.

Percentile Cut-off	Normal Range (ng/mL)
95%	25 – 200
90%	30 – 150
85%	40 – 120
80%	40 – 100

It is highly recommended that each laboratory should establish their own normal range for pepsinogen I based on local populations.

Patients with atrophic gastritis, as well as patients with stomach cancer would have a pepsinogen I level below 20 ng/mL. However, gastroendoscope and tissue biopsy should be used as final and confirmative diagnostic method.

LIMITATION OF THE PROCEDURE

1. Since there is no Gold Standard concentration available for human pepsinogen I measurement, the values of the assay standards were established by diluting a highly purified human pepsinogen I in a protein matrix.
2. For unknown sample value read directly from the assay that is greater than 300 ng/mL, it is recommended to measure a further diluted sample for more accurate measurement.
3. If there is not a microplate reader in your laboratory able to read beyond 2.0 at OD 450 nm, adjust the computer program for an assay without the calibrator level 5 from the calibrator set.
4. Bacterial or fungal contamination of serum specimens or reagents, or cross-contamination between reagents may cause erroneous results.
5. Water deionized with polyester resins may inactive the horseradish peroxidase enzyme.

QUALITY CONTROL

To assure the validity of the results, each assay should include adequate controls with known pepsinogen I levels. We recommend that all assays include the laboratory's own human serum based pepsinogen I controls in addition to those provided with this kit.

PERFORMANCE CHARACTERISTICS

Sensitivity

The sensitivity of this human pepsinogen I ELISA is 0.1 ng/mL as determined by measuring zero calibrator 16 times in the same assay and calculating the detection limit at 3 standard deviations above the pepsinogen I zero calibrator. The assay analytical sensitivity is approximately 0.5 ng/mL.

Specificity

This assay measures human pepsinogen I without any cross-reaction to human pepsinogen II.

Linearity

Two human serum samples were diluted with dilution buffer and assayed. The results, in the value of ng/mL, are as follows:

#	DILUTION	OBSERVED VALUE	EXPECTED VALUE	RECOVERY %
1	Neat	31.90	-	-
	1:2	16.21	15.95	102
	1:4	7.95	7.78	102
	1:8	3.73	3.99	93
	1:16	2.11	1.99	106
2	Neat	252.00	-	-
	1:2	125.27	126.00	99
	1:4	64.12	63.00	102
	1:8	31.25	31.50	99
	1:16	16.92	15.75	107

Precision

The intra-assay precision is validated by measuring two samples in a single assay with 20-replicate determinations.

Mean Pepsinogen I Value (ng/mL)	CV (%)
18.2	5.3
121.1	4.8

The inter-assay precision is validated by measuring two samples in duplicate in 12 individual assays.

Mean Pepsinogen I Value (ng/mL)	CV (%)
17.5	6.9
123.7	5.7

Recovery
Two patient samples were spiked with various amounts of human pepsinogen I and assayed. The results in the value of ng/mL, are as follows:

#	Orig. Value	Amount Spiked	Observed Value	Expected Value	Recovery %
1	18.6	10	12.6	14.3	88
		30	25.1	24.3	103
		90	56.2	54.3	103
2	121.1	10	61.3	65.6	93
		30	70.9	75.6	94
		90	104.7	105.6	99

"Hook" Effect
It was determined that this pepsinogen I ELISA did not show any high dose "hook" effect up to 10,000 ng/mL of pepsinogen I.

REFERENCES

1. Kuipers EJ. In through the out door: serology for atrophic gastritis. Eur J Gastroenterol Hepatol. 2003 Aug;15(8):877-9.

2. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003 Apr;98(4):735-9.

3. Miki K. [Serum pepsinogen I/II ratio test] Nippon Rinsho. 2003 Jan;61(1):92-5. Japanese.

4. So JB, Yeoh KG, Moochala S, Chachlani N, Ho J, Wong WK, Mack P, Goh PM. Serum pepsinogen levels in gastric cancer patients and their relationship with Helicobacter pylori infection: a prospective study. Gastric Cancer. 2002;5(4):228-32.

5. Korstanje A, den Hartog G, Biemond I, Lamers CB. The serological gastric biopsy: a non-endoscopical diagnostic approach in management of the dyspeptic patient: significance for primary care based on a survey of the literature. Scand J Gastroenterol Suppl. 2002;(236):22-6. Review.

6. Sipponen P, Harkonen M, Alanko A, Suovaniemi O. Diagnosis of atrophic gastritis from a serum sample. Clin Lab. 2002;48(9-10):505-15. Review.

7. Tabata H, Fuchigami T, Kobayashi H, Sakai Y, Nakanishi M, Tomioka K, Nakamura S, Matsumoto T, Fujishima M. Difference in degree of mucosal atrophy between elevated and depressed types of gastric epithelial tumors. Scand J Gastroenterol. 2001 Nov;36(11):1134-40.

8. Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR, Heinonen OP, Albanes D, Sande N, Virtamo J, Harkonen M.
Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Helsinki Gastritis Study Group. Scand J Gastroenterol. 2000 Sep;35(9):950-6.

9. Fernandez R, Vizoso F, Rodriguez JC, Merino AM, Gonzalez LO, Quintela I, Andicoechea A, Truan N, Diez MC. Expression and prognostic significance of pepsinogen C in gastric carcinoma. Ann Surg Oncol. 2000 Aug;7(7):508-14.

10. Kalinovskii VP, Gamaiunova VB, Shumakov AP, Khanson KP.
[Radioimmunoassay of serum pepsinogen I in chronic gastritis and stomach cancer] Vopr Onkol. 2000;46(2):153-5. Russian.

11. Shumakov AR, Fedorov SN, Kalinovskii VP, Khanson KP.
[Evaluation of pepsinogen A expression in stomach cancer] Vopr Onkol. 1999;45(3):238-40. Russian.

12. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA.
Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut. 1999 May;44(5):693-7.

13. Samloff IM and Taggart RT. Pepsinogens, pepsins, and peptic ulcer. Clinical and Investigative Medicine 1987;10:215-221

14. Samloff IM. Slow moving protease and the seven pepsinogens. Electrophoretic demonstration of the existence of eight proteolytic fractions in human gastric mucosa. Gastroentrology 1969;57:659-669

Pepsinogen I ELISA: Short Manual Assay Protocol

1. **25 µl Calibrators, controls and patient samples**
2. **100 µl Antibody mixture**

Incubate @ RT for 60 min

Wash 5 x

3. **100 µl TMB Substrate**

Incubate @ RT for 20 min

4. **100 µl Stop Solution**

5. **Read absorbance at 450 nm**

Revision date: 2015-08-11

	Used symbols
	Consult instructions for use
	Storage temperature
	Use by
LOT	Batch code
REF	Catalogue number
CONTROL	Control
IVD	In vitro diagnostic medical device
	Manufacturer
	Contains sufficient for <n> tests
WASH SOLN CONC	Wash solution concentrated
CAL 0	Zero calibrator
CAL N	Calibrator #
CONTROL N	Control #
Ag 125I	Tracer
Ab 125I	Tracer
Ag 125I CONC	Tracer concentrated
Ab 125I CONC	Tracer concentrated
	Tubes
INC BUF	Incubation buffer
ACETONITRILE	Acetonitrile
SERUM	Serum
DIL SPE	Specimen diluent
DIL BUF	Dilution buffer
ANTISERUM	Antiserum
IMMUNOADSORBENT	Immunoadsorbent
DIL CAL	Calibrator diluent
REC SOLN	Reconstitution solution
PEG	Polyethylene glycol
EXTR SOLN	Extraction solution
ELU SOLN	Elution solution
GEL	Bond Elut Silica cartridges
PRE SOLN	Pre-treatment solution
NEUTR SOLN	Neutralization solution
TRACEUR BUF	Tracer buffer
	Microtiterplate
Ab HRP	HRP Conjugate
Ag HRP	HRP Conjugate
Ab HRP CONC	HRP Conjugate concentrate
Ag HRP CONC	HRP Conjugate concentrate
CONJ BUF	Conjugate buffer
CHROM TMB CONC	Chromogenic TMB concentrate
CHROM TMB	Chromogenic TMB solution
SUB BUF	Substrate buffer
STOP SOLN	Stop solution
INC SER	Incubation serum
BUF	Buffer
Ab AP	AP Conjugate
SUB PNPP	Substrate PNPP
BIOT CONJ CONC	Biotin conjugate concentrate
PREC AGENT	Precipitating Agent
AVID HRP CONC	Avidine HRP concentrate
ASS BUF	Assay buffer
Ab BIOT	Biotin conjugate
Ab	Specific Antibody
SAV HRP CONC	Streptavidin HRP concentrate
NSB	Non-specific binding
2nd Ab	2nd Antibody
ACID BUF	Acidification Buffer
DIST	Distributor
TRAY	Incubation trays
PMSF	PMSF solution
	Protect from light
STRIP	Dot Strip
SUB	Substrate
EXTR SOLN CONC	Extraction Buffer Concentrate
CART	Cartridge
SAV HRP	Streptavidin HRP
PIPETTE	Pipette
WASH SOLN	Wash buffer